Regamey N, Tamm M, Wernli M, Witschi A, Thiel G, Cathomas G, Erb P
Institute for Medical Microbiology, University of Basel, Switzerland.
N Engl J Med. 1998 Nov 5;339(19):1358-63. doi: 10.1056/NEJM199811053391903.
Human herpesvirus 8 (HHV-8) has been detected in all forms of Kaposi's sarcoma, including transplantation-associated Kaposi's sarcoma. To investigate the possibility of transmission of HHV-8 through allografts, we measured the seroprevalence of HHV-8 before and after renal transplantation.
Using an enzyme-linked immunosorbent assay with the recombinant HHV-8 protein orf 65.2, we analyzed serum samples from 220 renal-transplant recipients for the presence of antibodies to HHV-8 on the day of transplantation and one year later. Positive results were confirmed by an indirect immunofluorescence assay that detects antibodies to latent antigen and by Western blotting. Follow-up lasted at least four years.
The seroprevalence of HHV-8 in graft recipients increased from 6.4 percent on the day of transplantation to 17.7 percent one year after transplantation. Seroconversion occurred within the first year after transplantation in 25 patients, and Kaposi's sarcoma developed in 2 of them within 26 months after transplantation. Sequential serum samples were obtained from 10 of the patients with seroconversion, and in 8 of these patients, IgM antibodies to HHV-8 appeared within three months after transplantation. In the case of six patients who seroconverted, serum samples from the donors were available, and five (83 percent) tested positive for HHV-8. In a control group of eight patients who were seronegative at the time of transplantation and who received allografts from HHV-8-negative donors, none seroconverted within the year after transplantation.
HHV-8 is transmitted through renal allografts and is a risk factor for transplantation-associated Kaposi's sarcoma.
在所有类型的卡波西肉瘤中均检测到人类疱疹病毒8型(HHV-8),包括移植相关的卡波西肉瘤。为了研究HHV-8通过同种异体移植传播的可能性,我们检测了肾移植前后HHV-8的血清阳性率。
使用重组HHV-8蛋白orf 65.2的酶联免疫吸附测定法,我们分析了220名肾移植受者在移植当天和一年后的血清样本中是否存在抗HHV-8抗体。通过检测针对潜伏抗原的抗体的间接免疫荧光测定法和蛋白质印迹法确认阳性结果。随访持续至少四年。
移植受者中HHV-8的血清阳性率从移植当天的6.4%升至移植后一年的17.7%。25名患者在移植后的第一年内发生血清转化,其中2人在移植后26个月内发生了卡波西肉瘤。从10名发生血清转化的患者中获取了连续的血清样本,其中8名患者在移植后三个月内出现了抗HHV-8 IgM抗体。在6名发生血清转化的患者中,可以获得供体的血清样本,其中5名(83%)HHV-8检测呈阳性。在一个由8名移植时血清阴性且接受来自HHV-8阴性供体的同种异体移植的患者组成的对照组中,一年内无人发生血清转化。
HHV-8通过肾同种异体移植传播,是移植相关卡波西肉瘤的一个危险因素。